nifer Posted March 14 Report Share Posted March 14 like SSRI's, but *enhances* reuptake, not inhibit it. does anyone have any info? Quote Link to comment Share on other sites More sharing options...
phuturephunk Posted March 14 Report Share Posted March 14 Originally posted by nifer like SSRI's, but *enhances* reuptake, not inhibit it. does anyone have any info? . . I can't see how enhanced reuptake would help, considering that when the Serotonin is taken back up it's no longer in the Synapse, which in turn means it's not being used . . . . . I think SSRE's are used to treat people with mania or bi polar are they not? . . . Quote Link to comment Share on other sites More sharing options...
nifer Posted March 14 Author Report Share Posted March 14 actually its being used as an antidepressant and an anxiolytic. i'm not sure how it works though Quote Link to comment Share on other sites More sharing options...
individual Posted March 15 Report Share Posted March 15 Never heard of em... I thought you misspelled it... That is weird though, I don't understand how an enhanced reuptake would help... maybe it makes the uptake more selective than an SSRI.I'm interested in knowing more.... Quote Link to comment Share on other sites More sharing options...
nifer Posted March 15 Author Report Share Posted March 15 i've done some searching on the web and found very little info on ssre's. i did come across one drug, stablon (tianeptine):Tianeptine is a novel antidepressant agent, both structurally (modified tricyclic) and in terms of its pharmacodynamic profile. Unlike other antidepressant agents, tianeptine stimulates the uptake of serotonin (5-hydroxytryptamine; 5-HT) in rat brain synaptosomes and rat and human platelets, increases 5-hydroxyindoleacetic acid (5-HIAA) levels in cerebral tissue and plasma, and reduces serotonergic-induced behaviour. Tianeptine reduces the hypothalamic-pituitary-adrenal response to stress, antagonises stress-induced behavioural deficits and prevents changes in cerebral morphology. The antidepressant efficacy of tianeptine, as shown in 2 trials of patients with major depression or depressed bipolar disorder with or without melancholia, is greater than that of placebo. In patients with major depression without melancholia or psychotic features, depressed bipolar disorder or dysthymic disorder, the antidepressant efficacy of short term (4 weeks to 3 months) tianeptine therapy appears to be similar to that of amitriptyline, imipramine and fluoxetine and may be superior to that of maprotiline in patients with coexisting depression and anxiety. However, submaximal dosages of amitriptyline and maprotiline were used in these studies. Preliminary evidence suggests that tianeptine may also be effective in patients with endogenous depression. Progressive therapeutic improvements have been observed with up to 1 year of tianeptine treatment, and long term therapy may reduce the rate of relapse or recurrence. Tianeptine is effective in the treatment of depression in elderly and post-alcohol-withdrawal patient subgroups. Tianeptine was more effective in reducing psychic anxiety than placebo in patients with major depression or depressed bipolar disorder with or without melancholia. The overall anxiolytic properties of tianeptine in patients with coexisting depression and anxiety appear to be similar to those of amitriptyline, imipramine and fluoxetine and may be superior to those of maprotiline, although submaximal dosages of amitriptyline and maprotiline were used. Studies of tianeptine in patients with primary anxiety have not been conducted. Tianeptine is well tolerated in the short (3 months) and long (up to 1 year) term. The incidence of dry mouth (38 vs 20%), constipation (19 vs 15%), dizziness/syncope (23 vs 13%), drowsiness (17 vs 10%) and postural hypotension (8 vs 3%) are greater with amitriptyline than with tianeptine. Insomnia and nightmares occur in more tianeptine than amitriptyline recipients (20 vs 7%). The relative lack of sedative, anticholinergic and cardiovascular adverse effects with tianeptine makes it particularly suitable for use in the elderly and in patients following alcohol withdrawal; these patients are known to have increased sensitivity to the adverse effects associated with psychotropic Quote Link to comment Share on other sites More sharing options...
individual Posted March 19 Report Share Posted March 19 Interesting.... thanks for the info! Quote Link to comment Share on other sites More sharing options...
Codica3 Posted March 22 Report Share Posted March 22 I always think it strange that in the far future, if I get my MD and whatnot, I will be prescribing and dealing with all these drugs and clients.. :laugh: Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.